It mimics endogenous GLP-1 with 94% homology but with extended half-life (~165 hours) due to albumin binding via a C-18 fatty di-acid side chain
But Mounjaro is a dual agonist, which means it mimics 2 hormones glucosedependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)
Side effects of compounded semaglutide are nausea, vomiting, diarrhea, constipation, and abdominal pain
Many clients experience reduced cravings and increased fullness after meals, though this varies
Its name comes from early findings that it increased delta-wave activity on EEG, which corresponds to deep, restorative sleep
Findings Additional insights we found via Centers for Medicare & Medicaid Services Previously, coverage for GLP-1s was barred under Medicare, and it's only covered under Medicaid in certain states, since states can choose whether to cover weight-loss drugs under Medicaid